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Background: In a phase 2 study, kidney transplant recipients of low immunologic risk who switched from a
calcineurin inhibitor (CNI) to belatacept had improved kidney function at 12 months postconversion versus
those continuing CNI therapy, with a low rate of acute rejection and no transplant loss.
Study Design: 36-month follow-up of the intention-to-treat population.
Setting & Participants: CNI-treated adult kidney transplant recipients with stable transplant function
(estimated glomerular filtration rate [eGFR], 35-75 mL/min/1.73 m2).
Interventions: At 6 to 36 months posttransplantation, patients were randomly assigned to switch to
belatacept-based immunosuppression (n 5 84) or continue CNI-based therapy (n5 89).
Outcomes: Safety was the primary outcome. eGFR, acute rejection, transplant loss, and death were also
assessed.
Measurements: Treatment exposure2adjusted incidence rates for safety, repeated-measures modeling for
eGFR, Kaplan-Meier analyses for efficacy.
Results: Serious adverse events occurred in 33 (39%) belatacept-treated patients and 36 (40%) patients in
the CNI group. Treatment exposure2adjusted incidence rates for serious infections (belatacept vs CNI, 10.21
vs 9.31 per 100 person-years) and malignancies (3.01 vs 3.41 per 100 person-years) were similar. More
patients in the belatacept versus CNI group had any-grade viral infections (14.60 vs 11.00 per 100 person-
years). No posttransplantation lymphoproliferative disorder was reported. Belatacept-treated patients had a
significantly greater estimated gain in mean eGFR (1.90 vs 0.07 mL/min/1.73 m2 per year; P for time-by-
treatment interaction effect 5 0.01). The probability of acute rejection was not significantly different for
belatacept (8.38% vs 3.60%; HR, 2.50 [95% CI, 0.65-9.65; P 5 0.2). HR for the comparison of belatacept
to the CNI group for time to death or transplant loss was 1.00 (95% CI, 0.14-7.07; P5 0.9).
Limitations: Exploratory post hoc analysis with a small sample size.
Conclusions: Switching patients from a CNI to belatacept may represent a safe approach to immuno-
suppression and is being further explored in an ongoing phase 3b trial.
Am J Kidney Dis. -(-):---. ª 2016 Published by Elsevier Inc. on behalf of the National Kidney Foundation,
Inc.
INDEX WORDS: Kidney transplant; renal transplantation; belatacept; calcineurin inhibitor (CNI); switch;
conversion study; immunosuppression; safety; adverse events; kidney function; acute rejection; graft loss;
phase 2 randomized controlled trial.The principal immunosuppressive therapies forkidney transplantation—the calcineurin in-
hibitors (CNIs) cyclosporine and tacrolimus—may
contribute to patient comorbidity via nephrotoxicity
and to cardiovascular risk (eg, hypertension, hyper-
cholesterolemia, and diabetes mellitus)1 and transplant
loss via chronic transplant injury.2 There is a need for
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y Dis. 2016;-(-):---response to an extent similar to that seen with CNIs, but
without the renal and cardiovascular toxicities that
contribute to transplant loss and patient death.3,4
Some CNI-avoiding or CNI-minimizing immuno-
suppressive regimens, many involving the mamma-
lian target of rapamycin (mTOR) inhibitors sirolimus
and everolimus, have been evaluated in kidney
transplant recipients.5 In prospective studies, patientsAddress correspondence to Josep M. Grinyó, MD, PhD,
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Grinyo´ et alswitching from CNI-based to mTOR inhibitor–based
immunosuppression showed signiﬁcant improve-
ments in kidney function at 12 months postconversion
versus patients who continue treatment with cyclo-
sporine or tacrolimus. However, mTOR inhibitor–
treated patients are more likely to have adverse events
(AEs), especially dyslipidemia and proteinuria.6-14
The frequency of proteinuria observed with mTOR
inhibitor–based immunosuppression is of concern
because proteinuria is associated with poor long-term
outcomes in kidney transplant recipients.15,16 More-
over, the early improvements in kidney function seen
with everolimus or sirolimus may not be sustained
over the long term (ie, beyond 1 year); some ran-
domized controlled studies have shown the signiﬁcant
differences favoring mTOR inhibitor–based over
CNI-based immunosuppression being maintained
for as long as 48 months postconversion,6,10,17-19
whereas others have reported loss of statistical sig-
niﬁcance as early as 24 months postconversion.8,11,20
Belatacept is the ﬁrst immunosuppressant that
selectively inhibits T-cell activation via costimulation
blockade to have been tested in kidney transplant re-
cipients. Accumulating evidence suggests that belata-
cept avoids the renal, cardiovascular, and metabolic
toxicities of CNI-based regimens. In 2 phase 3 studies
(Belatacept Evaluation of Nephroprotection and Efﬁ-
cacy asFirst-line ImmunosuppressionTrial [BENEFIT]
and BENEFIT–extended criteria donors [BENEFIT-
EXT]), patients treated de novo with belatacept had
comparable patient/transplant survival and superior
kidney function versus cyclosporine-treated patients at
1221,22 and 36 months posttransplantation.23,24 Long-
term follow-up data from the intention-to-treat pop-
ulations of BENEFIT and BENEFIT-EXT have shown
that belatacept provides sustained beneﬁt to kidney
function and a favorable safety proﬁle through 7 years
of treatment.25,26 In addition, at 7 years post-
transplantation, belatacept was associated with a 43%
reduction in risk for death or transplant loss in recipients
of standard-criteria donor kidneys.25
Belatacept was studied as conversion therapy in
patients maintained on CNI-based immunosuppres-
sion (cyclosporine or tacrolimus) in a phase 2
trial,27,28 the primary outcome of which was change
in estimated glomerular ﬁltration rate (eGFR) from
baseline to 12 months postrandomization.27 At 12
months postconversion, kidney function improve-
ments relative to baseline were statistically
signiﬁcantly greater in patients who switched to
belatacept-based immunosuppression versus those
who continued CNI therapy (7.0 vs 2.1 mL/min/
1.73 m2; P 5 0.006). Moreover, the switch from a
CNI to belatacept was not associated with increased
risk for death or transplant loss. Acute rejection
occurred in 6 of 84 (7%) patients in the belatacept2treatment group, all within the ﬁrst 6 months of
treatment, and in no patient in the CNI treatment
group.27 Among patients who continued to participate
in the study beyond month 12, mean change in eGFR
from baseline to month 24 remained greater in pa-
tients randomly assigned to switch to belatacept
versus those who remained on CNI treatment (8.8 vs
0.3 mL/min/1.73 m2). Between months 12 and 24,
acute rejection occurred in no belatacept-treated pa-
tient and in 3 patients who remained on CNI-based
immunosuppression.28 We summarize outcomes at
36 months postrandomization in the intention-to-treat
population of this phase 2 conversion study.
METHODS
Phase 2 Study Design
The design of this open-label multicenter study has been
described (ClinicalTrials.gov study number NCT00402168).27,28
Brieﬂy, study participants were adults receiving a living or
deceased donor kidney transplant in the 6 to 36 months prior to
trial enrollment. To be eligible, patients had to be receiving CNI-
based maintenance immunosuppression and have stable kidney
function (eGFR, 35-75 mL/min/1.73 m2). Patients were randomly
assigned (1:1) to switch to 5 mg/kg of belatacept (intravenous;
days 1, 15, 29, 43, and 57 and every 28 days thereafter) or to
remain on existing CNI-based therapy, with randomization strati-
ﬁed by CNI regimen (cyclosporine or tacrolimus) and site.27 To
ensure that all patients had the opportunity to receive belatacept,
patients randomly assigned to continuous CNI-based immuno-
suppression who consented to participate in the long-term exten-
sion were allowed to switch to belatacept after month 24, if
deemed clinically appropriate by the study investigator (n 5 16).
The study was approved by the ethics committees/institutional
review boards at participating centers and conformed to Good
Clinical Practice guidelines and the Declaration of Helsinki. All
patients provided written informed consent.
Outcomes and Analyses
The primary objective of this analysis was to assess the ongoing
safety and tolerability of belatacept in the intention-to-treat pop-
ulation. AEs and serious AEs were mapped to Medical Dictionary
for Regulatory Activities (MedDRA), version 14.0. Because
treatment duration varied between patients, incident rates of AEs
and serious AEs were adjusted for each patient’s treatment
exposure and calculated as number of AEs and serious AEs
divided via duration of treatment exposure in 100 person-years.
Secondary end points included eGFR (determined using the 6-
variable MDRD [Modiﬁcation of Diet in Renal Disease] Study
equation29), acute rejection, death, and transplant loss.
Mean eGFRs and 95% conﬁdence intervals (CIs) were deter-
mined from month 1 to month 36 using a repeated-measures
model with an unstructured covariance matrix. This model takes
into account between-patient variability and the intrapatient cor-
relation of eGFR measurements over time and included time,
treatment, and a time-by-treatment interaction (no adjustment was
made for other potentially confounding covariates). Time was
regarded as a categorical variable (intervals of 3 months up to
month 12 and every 6 months thereafter). Missing data were
assumed to be missing completely at random. Sensitivity analysis
was performed in which eGFR values that were missing due to
death or transplant loss were imputed as zero.
A slope-based model was also used to determine whether there
was a difference between the slope for the belatacept group and theAm J Kidney Dis. 2016;-(-):---
Switching to Belatacept: 3-Year Outcomesslope for the CNI group. The slope-based model assumed that the
relationship between eGFR values over time was linear. The dif-
ference between slopes was tested with the use of a contrast state-
ment within the SAS model (SAS software, version 9.2; SAS
Institute Inc). Time was regarded as a continuous variable; treat-
ment, as a ﬁxed effect; and intercept and time, as random effects (no
adjustment was made for other potentially confounding covariates).
Sensitivity analysis was performed in which eGFR values that were
missing due to death or transplant loss were imputed as zero.
The cumulative event rate for acute rejection was calculated for
each treatment group using the Kaplan-Meier method. Time to
death and/or time to transplant loss in each treatment group were
determined using the Kaplan-Meier method and compared using
log-rank test. No adjustment was made for multiplicity testing. The
development of donor-speciﬁc antibodies was assessed centrally at
baseline; months 6, 12, 24, and 36; and the time of suspected acute
rejection episodes. Hazard ratios (HRs) and 95% CIs for the ef-
ﬁcacy end points were derived using Cox regression.
RESULTS
Patient Disposition
In total, 74 of 84 (88%) belatacept-treated patients and
72 of 89 (81%) patients in the CNI group were followed
up for the full 36-month period. Five belatacept-treated
patients discontinued treatment by month 36 due to
lack of efﬁcacy (n5 2), AE (n5 1 [polyoma virus–
associated nephropathy]), death (n5 1), and other
(n5 1). Fourteen patients in the CNI treatment group
discontinued treatment by month 36 for unknown
reasons (n5 4), withdrawal of consent (n5 3), AE
(n5 2 [pulmonary edema and nephropathy, n5 1;
cellulitis, n5 1]), other (n5 2), administrative reason
(n5 1), death (n5 1), and lack of efﬁcacy (n5 1). The
CNI group also included 16 patients who switched to
belatacept after month 24, as permitted in the study
protocol. Overall, treatment groups were balanced in
baseline demographics, immunologic factors, and donor
characteristics (Table 1).
Safety
At 36 months postrandomization, the cumulative
frequency of serious AEs was similar for the belata-
cept (33 of 84 [39%]) and CNI (36 of 89 [40%])
groups. The incidence rate of serious infections per
100 person-years of treatment exposure was similar
for the belatacept and CNI groups (10.21 and 9.31 per
100 person-years, respectively; Table 2). However,
more belatacept-treated patients had any-grade viral
infections (14.60 per 100 person-years) versus those
in the CNI (11.00 per 100 person-years) treatment
group. The most common any-grade viral infections
were inﬂuenza, herpes, and cytomegalovirus viremia.
More patients had any-grade fungal infections in the
belatacept group (9.73 per 100 person-years) than in
the CNI group (2.58 per 100 person-years); the most
common types of fungal infections were onychomy-
cosis and tinea versicolor. The frequency of any-
grade malignancies was similar in the belatacept
(3.01 per 100 person-years) and CNI (3.41 per 100Am J Kidney Dis. 2016;-(-):---person-years) groups; the most common malignancies
were basal cell carcinoma and squamous cell carci-
noma. No patient in either treatment group developed
posttransplantation lymphoproliferative disorder.
Serious proteinuria occurred in 1 belatacept-treated
patient (0.42 per 100 person-years) and no patient in
the CNI treatment group.
Kidney Function
From month 1 to month 36, mean eGFR increased
for the belatacept treatment group, but not for the CNI
treatment group (Fig 1). Mean eGFRs at months 12,
24, and 36 in the belatacept group were 60.3, 62.4,
and 62.4 mL/min/1.73 m2, respectively. Correspond-
ing values in the CNI group were 56.9, 55.0, and
55.6 mL/min/1.73 m2, respectively. The estimated
difference in eGFRs signiﬁcantly favored belatacept-
based versus continued CNI-based immunosuppres-
sion (P5 0.01 for the overall treatment effect). In
terms of change in mean eGFR from month 1 to
month 36, the slope-based analysis showed that pa-
tients randomly assigned to the belatacept group had
an estimated gain in eGFRs of 1.90 (95% CI, 0.89-
2.92) mL/min/1.73 m2 per year, whereas those
randomly assigned to the CNI treatment group had an
estimated gain in eGFRs of 0.07 (95% CI, 20.96 to
1.09) mL/min/1.73 m2 per year. eGFR slopes diverged
signiﬁcantly between the 2 treatment groups over time
(P for the time-by-treatment interaction effect5 0.01).
Sensitivity analysis in which eGFRs that were
missing due to death or transplant loss were imputed
as zero yielded similar results. Mean eGFRs at
months 12, 24, and 36 in the belatacept group were
60.3, 61.9, and 61.0 mL/min/1.73 m2, respectively.
Corresponding values in the CNI group were 56.4,
54.3, and 54.7 mL/min/1.73 m2, respectively. The
estimated difference in eGFRs signiﬁcantly favored
belatacept-based versus continued CNI-based immu-
nosuppression (P 5 0.02 for the overall treatment
effect). In terms of change in mean eGFR from month
1 to month 36, the slope-based analysis with impu-
tation showed that patients randomly assigned to the
belatacept group had an estimated gain in eGFRs of
1.39 (95% CI, 0.153-2.626) mL/min/1.73 m2 per
year, whereas those randomly assigned to the CNI
group had an estimated change of 20.215 (95%
CI, 21.453 to 1.023) mL/min/1.73 m2 per year. In
contrast to the slope-based analysis without imputa-
tion, eGFR slopes deriving from sensitivity analysis
did not diverge signiﬁcantly between the belatacept
and CNI treatment groups (P for the time-by-
treatment interaction effect 5 0.07).
Acute Rejection
At month 36 postrandomization, cumulative rates
for the proportion of patients with acute rejection in3
Table 1. Baseline Characteristics
Belatacept (n 5 84) CNI (n 5 89)
Mean age, y 45.3 6 13.5 44.36 13.0
Male sex 66 (79) 60 (67)
Race
White 44 (52) 53 (60)
Black/African American 6 (7) 4 (5)
Asian 16 (19) 12 (14)
Other 18 (21) 20 (22)
Geographic region
North America 28 (33) 25 (28)
South America 28 (33) 31 (35)
Europe 15 (18) 22 (25)
Other 13 (16) 11 (12)
Reported cause of ESRD
Glomerulonephritis 23 (27) 14 (16)
Diabetes 7 (8) 10 (11)
Polycystic kidneys 9 (11) 9 (10)
Renovascular/hypertensive nephrosclerosis 7 (8) 10 (11)
Congenital, familial, and metabolic 3 (4) 3 (3)
Other 35 (42) 43 (48)
Previous no. of transplants
0 74 (88) 77 (87)
1 10 (12) 10 (11)
2 0 (0) 2 (2)
Highest panel-reactive antibodies
,20% 63 (75) 64 (72)
$20% 3 (4) 5 (6)
Missing 18 (21) 20 (23)
Baseline eGFR, mL/min/1.73 m2 53.5 6 11.0 54.56 10.3
Time from transplantation to randomization, mo 19.4 6 9.2 20.1 6 9.4
CNI
Cyclosporine 37 (44) 39 (44)
Trough serum cyclosporine level, ng/mLa 160.26 41.81 154.46 38.08
Tacrolimus 47 (56) 50 (56)
Trough serum tacrolimus level, ng/mLa 7.26 1.77 7.5 6 1.44
Adjunctive immunosuppressive agentsb
Azathioprine 6 (7) 3 (3)
MMF/MPA 77 (93) 83 (94)
Sirolimus 1 (1) 0 (0)
Systemic corticosteroidsb 73 (88) 71 (81)
Note: Continuous variables given as mean 6 standard deviation; categorical variables, as count (proportion).
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; MMF,
mycophenolate mofetil; MPA, mycophenolic acid.
aCyclosporine trough levels based on data available for 36 patients in the belatacept group and 37 patients in the CNI group;
tacrolimus trough levels based on data available for 45 patients in the belatacept group and 46 patients in the CNI group.
bPrerandomization data for adjunctive agents were not available for 3 patients in the CNI group; data were based on randomly
assigned treated patients (belatacept, n 5 83; CNI, n5 88).
Adapted with permission from Rostaing et al.27
Grinyo´ et althe belatacept and CNI groups were 8.38% and
3.60%, respectively. HR for the comparison of
belatacept-based versus continuous CNI-based
immunosuppression for the probability of acute
rejection was 2.50 (95% CI, 0.65-9.65; p 5 0.2;
Fig 2). In the belatacept group, 1 patient each had4grade IA, grade IB, and grade IIB acute rejection, and
4 patients had grade IIA acute rejection by month 36.
In the CNI group, 1 patient had grade IB acute
rejection, and 2 patients had grade IIA acute rejection
by month 36. No patient in either treatment group had
grade III acute rejection.Am J Kidney Dis. 2016;-(-):---
Table 2. Cumulative Incidence Rates of Selected
Adverse Events
Event
Belatacept
(n 5 84)
CNI
(n 5 89)
Serious infections 10.21 9.31
Urinary tract infection 2.57 0.41
Gastroenteritis 2.13 0.82
Pyelonephritis 0.84 0.83
Upper respiratory tract infection 0.84 0.00
Escherichia spp urinary tract infection 0.41 0.83
Pneumonia 0.41 0.82
Cellulitis 0.00 0.82
Cytomegalovirus infection 0.00 0.83
Any-grade viral infections 14.60 11.00
Influenza 4.45 4.54
Herpes virus infection 1.71 0.84
Cytomegalovirus viremia 1.71 0.00
Oral herpes 1.28 1.27
Herpes zoster 1.29 0.85
Epstein-Barr viremia 1.27 0.00
Cytomegalovirus infection 0.84 0.85
BK virus infection 0.85 0.00
Anogenital warts 0.00 0.84
Any-grade fungal infections 9.73 2.58
Onychomycosis 2.13 1.27
Tinea versicolor 2.19 0.00
Fungal infection 1.28 0.42
Fungal skin infection 0.85 0.84
Body tinea 0.85 0.00
Vulvovaginal candidiasis 0.84 0.00
Any-grade malignancies 3.01 3.41
Basal cell carcinoma 1.27 2.11
Squamous cell carcinoma of the skin 0.41 1.23
Note: Values given are incidence rates per 100 person-years
of treatment exposure. Only adverse events occurring in $2% of
patients in either treatment group are reported.
Abbreviation: CNI, calcineurin inhibitor.
Switching to Belatacept: 3-Year OutcomesPatient and Transplant Survival
By month 36, one patient in each treatment group
died and one patient in each group had transplant loss.
Kaplan-Meier–estimated rates of death or transplantFigure 1. Mean estimated glomerular filtration rate (eGFR) from m
calcineurin inhibitor.
Am J Kidney Dis. 2016;-(-):---loss in the belatacept group at months 12, 24, and 36
were 0.00%, 1.23%, and 2.47%, respectively. Corre-
sponding values in the CNI group were 1.14%,
2.37%, and 2.37%, respectively. HR for the compar-
ison of the belatacept group with the CNI group was
1.00 (95% CI, 0.14-7.07; P 5 0.9; Table 3).
Kaplan-Meier–estimated rates of death in the
belatacept group at months 12, 24, and 36 were
0.00%, 0.00%, and 1.25%, respectively. Corre-
sponding values in the CNI group were 1.14%,
1.14%, and 1.14%, respectively. HR for the compar-
ison of the belatacept group with the CNI group was
1.02 (95% CI, 0.06-16.27; P 5 0.9; Table 3).
Kaplan-Meier–estimated rates of death-censored
transplant loss in the belatacept group at months 12,
24, and 36 were 0.00%, 1.23%, and 1.23%, respec-
tively. Corresponding values in the CNI group were
0.00%, 1.25%, and 1.25%, respectively. HR for the
comparison of the belatacept group with the CNI
group was 0.98 (95% CI, 0.06-15.69; P 5 0.9;
Table 3).
Donor-Speciﬁc Antibodies
The development of donor-speciﬁc antibodies was
infrequent and similar between treatment groups.
Cumulative rates for the proportion of patients who
developed de novo donor-speciﬁc antibodies by
month 36 in the belatacept and CNI groups were
0.00% and 2.30%, respectively.
DISCUSSION
This analysis demonstrated the potential for kidney
transplant recipients with stable transplant function to
convert from CNI-based to belatacept-based immu-
nosuppression. Overall, conversion to belatacept was
well tolerated and was associated with improved
kidney function over 36 months.
Compared to the continuous CNI treatment
group, numerically fewer patients randomly assigned
to switch to belatacept-based immunosuppressiononth 1 to month 36. Abbreviations: CI, confidence interval; CNI,
5
Figure 2. Probability of acute rejection. Abbreviations: CI,
confidence interval; CNI, calcineurin inhibitor.
Grinyo´ et aldiscontinued treatment prior to month 36 (6% vs
16%, respectively). Safety proﬁles of both treatment
groups were similar over 36 months, although treat-
ment exposure2adjusted incidence rates of any-grade
viral infections and any-grade fungal infections were
numerically higher with belatacept-based versus
continued CNI-based therapy. These data support the
favorable tolerability of belatacept that was observed
in this cohort at 12 and 24 months post-
conversion.27,28 Dyslipidemia and proteinuria, which
can lead to treatment discontinuation, are AEs com-
mon to mTOR inhibitor–based immunosuppres-
sion.9,12,14,15,19 Serious proteinuria was an infrequent
event in this study, occurring in only 1 belatacept-
treated patient and in no patient who continued
CNI-based immunosuppression.
Compared with patients who remained on tacroli-
mus or cyclosporine treatment, those who switched to
belatacept sustained early improvements in kidney
function for up to 36 months postconversion. Based
on results from the mixed model, belatacept-treated
patients had an estimated gain in eGFRs of
1.90 mL/min/1.73 m2 per year. This increase is both
clinically and statistically signiﬁcant and was sup-
ported by sensitivity analysis in which eGFR values
that were missing because of death or transplant loss
were imputed as zero. However, statistical signiﬁ-
cance was not reached in this slope-based sensitivity
analysis, likely due in part to the increased variabilityTable 3. Time to Death and/or Transplant Loss
Belatacept vs CNI
Time to death or transplant loss 1.00 (0.14-7.07)
Time to death 1.02 (0.06-16.27)
Time to death-censored transplant loss 0.98 (0.06-15.69)
Note: Values are given as hazard ratio (95% confidence in-
terval). P5 0.9 for all.
Abbreviation: CNI, calcineurin inhibitor.
6introduced by adding zero values. In addition, dif-
ferences in kidney function measured at 36 months
postrandomization may have been confounded by the
16 patients who switched from CNI-based to
belatacept-based immunosuppression after month 24.
However, given the kidney function improvements
observed in the belatacept treatment group, this would
diminish the statistical and clinical differences be-
tween treatment arms in favor of CNI-based
immunosuppression.
Improvements in kidney function have also been
observed in kidney transplant recipients converting
from CNI-based to mTOR inhibitor–based immuno-
suppression; in the ZEUS and CENTRAL studies of
everolimus and the SMART study of sirolimus, pa-
tients who switched to a CNI-free regimen had
signiﬁcantly higher GFRs at 12 months postswitch
versus those who continued CNI-based therapy.9,12,13
Statistically signiﬁcant differences in favor of mTOR
inhibitor–based therapy were seen in the ZEUS and
SMART studies at 36 months postswitch,17,18 but not
in the CENTRAL study.20 Thus, mTOR inhibitor–
based regimens may not consistently sustain im-
provements in kidney function over the long term.
This is supported by the randomized ASCERTAIN
(Assessment of Everolimus in Addition to Calci-
neurin Inhibitor Reduction in the Maintenance of
Renal Transplant Recipients) and Spare-the-Nephron
(sirolimus) studies, in which no statistically signiﬁ-
cant differences in measured GFRs were seen be-
tween the CNI and mTOR inhibitor treatment groups
at 24 months postswitch.6,8
Cumulative rates of acute rejection up to month 36
were low; however, acute rejection rates were
numerically higher and occurred earlier among pa-
tients randomly assigned to the belatacept versus the
continued CNI treatment group. There were few
deaths and few transplant losses, with no statistically
signiﬁcantly differences between treatment groups in
risk for death and/or transplant loss over 36 months.
The development of de novo donor-speciﬁc anti-
bodies was an infrequent occurrence in this phase 2
study. This ﬁnding, coupled with the fact that few
patients receiving ﬁrst-line treatment with belatacept-
based immunosuppression in the phase 3 clinical tri-
als developed de novo donor-speciﬁc antibodies,21-26
suggest that belatacept may be associated with a
lower incidence of donor-speciﬁc antibody formation.
Data for the incidence of donor-speciﬁc antibody for-
mation following conversion from CNI-based to
mTOR inhibitor–based immunosuppression are
limited; however, a retrospective subanalysis of the
ZEUS and CRAD001ADE13 trials found that conver-
sion to everolimus was associated with increased risk
for both de novo donor-speciﬁc antibody development
and antibody-mediated rejection.30Am J Kidney Dis. 2016;-(-):---
Switching to Belatacept: 3-Year OutcomesThere are limitations associated with the present
analysis that may preclude deﬁnitive interpretation of
the results. First, sample sizes were small. Second, the
trial design was open label, which may have intro-
duced bias. Last, the large range of times between
transplantation and conversion (6-36 months) may
have confounded results; studies have demonstrated
that patient outcomes may be improved with earlier
conversion from CNI-based regimens.16
Despite these limitations, our results suggest that
the improvements in kidney function seen in patients
who switched from CNI-based to belatacept-based
immunosuppression were sustained over 36 months
and may help preserve long-term transplant function.
This exploratory analysis indicates that switching
from a CNI-based to a belatacept-based regimen may
represent a safe and effective clinical approach to
long-term immunosuppression, one that is being
further explored in an ongoing phase 3b trial
(ClinicalTrials.gov study number NCT01820572).
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